1006028-37-0

1006028-37-0 structure

Name: NF 546
Chemical Name: Tetrasodium {carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonyliminobenzene-1,2,4-triylbis(methylene)]}tetrakis[hydrogen (phosphonate)]
CAS Number: 1006028-37-0
Molecular Formula: C₄₇H₄₄N₆Na₄O₁₇P₄
Molecular Weight: 1180.736
Catalog: Signaling Pathways GPCR/G Protein P2Y Receptor
Create Date: 2018-07-10 00:32:07
Modify Date: 2025-08-26 17:28:07
NF546 is a selective non-nucleotide P2Y11 agonist with a pEC50 of 6.27. NF546 stimulates release of interleukin-8 from human monocyte-derived dendritic cells[1].

Name	Tetrasodium {carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonyliminobenzene-1,2,4-triylbis(methylene)]}tetrakis[hydrogen (phosphonate)]
Synonyms	Tetrasodium {carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonyliminobenzene-1,2,4-triylbis(methylene)]}tetrakis[hydrogen (phosphonate)] Phosphonic acid, [carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonyliminobenzene-1,2,4-triylbis(methylene)]]tetrakis-, sodium salt (1:4)

Description	NF546 is a selective non-nucleotide P2Y11 agonist with a pEC50 of 6.27. NF546 stimulates release of interleukin-8 from human monocyte-derived dendritic cells[1].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> P2Y Receptor Research Areas >> Inflammation/Immunology
Target	pEC50: 6.27 (P2Y11)[1]
In Vitro	NF546 is relatively selective for P2Y11 over P2Y1, P2Y2, P2Y4, P2Y6, P2Y12, P2X1, P2X2, and P2X2-X3. NF546 (100 μM; 24 hours) is equi-efficacious in stimulating TSP-1 release and inhibiting the LPS-induced release of IL-12p70 in human monocyte-derived dendritic cells[1].
References	[1]. Meis S, et al. NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J Pharmacol Exp Ther. 2010 Jan;332(1):238-47.